| Angela S Camfield, MD | |
|
920 Stanton L Young Blvd, Oklahoma City, OK 73104-5036 | |
| (405) 271-4351 | |
| (405) 271-8695 |
| Full Name | Angela S Camfield |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology - Pediatric Anesthesiology |
| Location | 920 Stanton L Young Blvd, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356384887 | NPI | - | NPPES |
| 182549901 | Medicaid | TX |
| Entity Name | Sheridan Healthcorp Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629781711 PECOS PAC ID: 3173429693 Enrollment ID: O20031208000355 |
News Archive
Americans are using more out-of-network care and paying more out of pocket for behavioral health care than for treatment of other conditions, despite efforts to increase coverage and access to mental health services, according to new research.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
A new therapeutic may help reverse chemical imbalances made to the brain by habitual drug use and could one day help recovering drug addicts avoid future drug use.
The Food and Drug Administration has an important role in our nation's food supply to ensure that consumers are not misled by positive or negative claims about the food and beverages they purchase and consume. In doing so, their mandate is to use robust and comprehensive scientific evidence as the basis of their recommendations.
› Verified 9 days ago
| Entity Name | Jupiter Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700073848 PECOS PAC ID: 0547348211 Enrollment ID: O20080421000429 |
News Archive
Americans are using more out-of-network care and paying more out of pocket for behavioral health care than for treatment of other conditions, despite efforts to increase coverage and access to mental health services, according to new research.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
A new therapeutic may help reverse chemical imbalances made to the brain by habitual drug use and could one day help recovering drug addicts avoid future drug use.
The Food and Drug Administration has an important role in our nation's food supply to ensure that consumers are not misled by positive or negative claims about the food and beverages they purchase and consume. In doing so, their mandate is to use robust and comprehensive scientific evidence as the basis of their recommendations.
› Verified 9 days ago
| Entity Name | Bethesda Anesthesia Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801054473 PECOS PAC ID: 3971670795 Enrollment ID: O20080920000183 |
News Archive
Americans are using more out-of-network care and paying more out of pocket for behavioral health care than for treatment of other conditions, despite efforts to increase coverage and access to mental health services, according to new research.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
A new therapeutic may help reverse chemical imbalances made to the brain by habitual drug use and could one day help recovering drug addicts avoid future drug use.
The Food and Drug Administration has an important role in our nation's food supply to ensure that consumers are not misled by positive or negative claims about the food and beverages they purchase and consume. In doing so, their mandate is to use robust and comprehensive scientific evidence as the basis of their recommendations.
› Verified 9 days ago
| Entity Name | Galloway Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689989139 PECOS PAC ID: 0143402917 Enrollment ID: O20110315001054 |
News Archive
Americans are using more out-of-network care and paying more out of pocket for behavioral health care than for treatment of other conditions, despite efforts to increase coverage and access to mental health services, according to new research.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
A new therapeutic may help reverse chemical imbalances made to the brain by habitual drug use and could one day help recovering drug addicts avoid future drug use.
The Food and Drug Administration has an important role in our nation's food supply to ensure that consumers are not misled by positive or negative claims about the food and beverages they purchase and consume. In doing so, their mandate is to use robust and comprehensive scientific evidence as the basis of their recommendations.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Angela S Camfield, MD 178 Carmela Ct, Jupiter, FL 33478-5401 Ph: () - | Angela S Camfield, MD 920 Stanton L Young Blvd, Oklahoma City, OK 73104-5036 Ph: (405) 271-4351 |
News Archive
Americans are using more out-of-network care and paying more out of pocket for behavioral health care than for treatment of other conditions, despite efforts to increase coverage and access to mental health services, according to new research.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
A new therapeutic may help reverse chemical imbalances made to the brain by habitual drug use and could one day help recovering drug addicts avoid future drug use.
The Food and Drug Administration has an important role in our nation's food supply to ensure that consumers are not misled by positive or negative claims about the food and beverages they purchase and consume. In doing so, their mandate is to use robust and comprehensive scientific evidence as the basis of their recommendations.
› Verified 9 days ago
Dr. Elizabeth Anne Williams, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 6201 Beaver Creek Rd, Oklahoma City, OK 73162 Phone: 405-210-4198 Fax: 405-703-7595 | |
Dr. Steven J Lantier, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 9500 Broadway Ext, Oklahoma City, OK 73114 Phone: 405-475-0680 | |
Dr. Martin J Lopez, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4525 S Klein Ave, Ste 900, Oklahoma City, OK 73109 Phone: 405-636-1797 | |
Betty J Haywood, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 750 Ne 13th St, Oac 200, Oklahoma City, OK 73104 Phone: 405-271-4351 Fax: 405-271-8695 | |
Dr. Suhal S Mahid, MD, PHD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1000 N Lee Ave, Oklahoma City, OK 73102 Phone: 405-272-8000 | |
Dr. Lauren L. Fitzgerald, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4401 S Western Ave, Oklahoma City, OK 73109 Phone: 918-392-2944 Fax: 918-664-2521 | |
Sathish Ramanathan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 920 Stanton L Young Blvd # Wp1140, Oklahoma City, OK 73104 Phone: 405-271-4351 Fax: 405-271-8695 |